3 Trials That Will Change My Practice with Dr Muthiah Vaduganathan

(4:55)

Muthiah Vaduganathan, MD, MPH: Using SGLT2 Inhibitors With Diuretics or RAAS Inhibitors

(3:17)

05 Muthiah Vaduganathan Biomarkers in Heart Failure

(24:54)

Muthiah Vaduganathan, MD: Comprehensive Therapy for HFrEF

(8:17)

ADA 2020: Findings from EMPA-REG OUTCOME trial — Dr Muthiah Vaduganathan

(10:30)

Muthiah Vaduganathan, MD, MPH: Prescribing SGLT2 Inhibitors to Patients with an EGFR of 30 or Lower

(5:50)

Historic Evolution of Mineralocorticoid Receptors CV and Renal Protection - Muthiah Vaduganathan, MD

(19:47)

#11 Diabeto-Cardiology: From the Cardiologist's perspective with Muthiah Vaduganathan, MD

(52:11)

382. SGLT Inhibitors: The Data Supporting SGLT Inhibition with Dr. Muthiah Vaduganathan

(48:47)

Muthiah Vaduganathan, MD: Barriers to Optimal Prescribing of SGLT2i and GLP-1 RA Agents

(3:22)

Historic Evolution of Mineralocorticoid Receptors CV and Renal Protection - Muthiah Vaduganathan, MD

(19:47)

Dr. Muthiah Vaduganathan presents Practical Guide to Implementation of SGLT2i in Clinical Practice.

(41:4)

HCPLive Five at ESC 2024

(9:27)

ESC TV at #ESCCongress 2022 - DELIVER and EMPEROR-Preserved

(2:16)

ESC 2022: EMPEROR-Preserved \u0026 DELIVER Meta-Analysis: SGLT2is in Heart Failure | Dr Vaduganathan

(5:2)

SGLT2i in patients with heart failure. Results of two meta-analysis

(3:31)

Time to Significant Benefit of Finerenone in Patients with Heart Failure | JACC | HFSA 2024

(7:6)

Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020

(18:26)

Panel Discussion - Edward Fry, MD; Annapoorna Kini, MD; Roxana Mehran, MD; Muthiah Vaduganathan, MD

(28:20)

Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment

(3:50)